Summary

Transcatheter aortic valve implantation (TAVI) is a viable treatment option for high-risk surgical patients with severe symptomatic aortic stenosis (AS). The SAPIEN XT™ (SXT) and CoreValve® with AccuTrak™ delivery system (MCVAT) are new generation devices currently available in Europe for transfemoral TAVI. To date, no prospective comparisons between these 2 devices have been undertaken. The objectives of this study were to assess the overall clinical outcomes of TAVI and to compare the SXT versus MCVAT devices in a nonrandomized registry population.